Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00336635
NCT00336635CompletedPhase 1

Randomized, Double Blind, Placebo Control Study to Evaluate the Safety and Immunogenicity of CJ-50300 in Healthy Volunteers : Phase I

Seoul National University Hospital2 sites in 2 countries24 target enrollmentStarted: June 2006Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
24
Locations
2
Primary Endpoint
safety and immunogenicity
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The currently available stock of smallpox vaccine would be insufficient in the face of an incident of smallpox attack. Thus, new manufacturing methods for smallpox vaccine is urgently needed because previous manufacturing methods using calf lymph are no longer acceptable in the view of current standards. Recently, CJ corporation in Republic of Korea has developed cell-culture derived smallpox vaccine (CJ-50300) which was manufactured by infecting MRC-5 cells. The aim of this phase 1 clinical trial were to assess safety, reactogenicity, and immunogenicity of CJ-50300.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Single Group
Primary Purpose
Prevention
Masking
Double

Eligibility Criteria

Ages
20 Years to 28 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Healthy Korean male and female subjects between 20 and 28 years of age at the time of screening visit.
  • •Willing to participate and have signed the informed consent form
  • •In good general health, without clinically skin diseases history, physical examination or laboratory test results
  • •Hematocrit >33% for women; >38% for men
  • •White cell count 3,300-12,000/mm3
  • •Total lymphocyte count > 800 cells/mm3

Exclusion Criteria

  • •Diseases or conditions that cause immunodeficiency (For examples; HIV AIDS, leukemia, lymphoma, generalized malignancy, agammaglobulinemia, history of transplantation, therapy with alkylating agents, antimetabolites, radiation, or oral or parenteral corticosteroids).
  • •In close physical contact (household or at work) with an individual who has the diseases or conditions that cause immunodeficiency
  • •history or present of eczema or atopic dermatitis
  • •Allergy or sensitivity to any known components of vaccine or other medicines
  • •In close physical contact (household or at work) with an individual who has acute or chronic skin conditions such as dermatitis, exfoliative dermatitis
  • •Subjects with inflammatory ophthalmic disease requiring steroid therapy
  • •Subjects who are planning for blood donations
  • •Autoimmune disease such as lupus erythematosus
  • •Subjects who work in medical institution
  • •Household contacts with women who are pregnant or breast-feeding
  • •Female Subjects who are pregnant or breast-feeding and have positive result by serum pregnancy test or urine pregnancy test, or do not using approved contraceptives such as sterilization, contraceptive ring injectable, combined oral contraceptive pills and barrier contraceptive, combined hormone-based therapy, contraceptive cream, contraceptive jelly, diaphragm or condoms
  • •Subjects household member <1 year old or work with children <1 year old
  • •Subjects with a known history of Cardiac disease or have three or more of the following risk factors: hyperpiesia, obesity, hyperlipidemia, glucosuria, sclerosis, cerebral arteriosclerosis
  • •Receipt of immunoglobulin and steroid within 14 days of vaccination
  • •Receipt of investigational research agents within 120 days of vaccination
  • •HBsAg seropositive
  • •HCV antibody seropositive
  • •HIV seropositive
  • •Subjects having fever (oral temperature > 38℃) or severe nutrition disorder
  • •Blood donation within 12 weeks in advance screening visit
  • •Subject who are not suitable to participate in study according to invesigator's judgement

Outcomes

Primary Outcomes

safety and immunogenicity

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials

Completed
Not Applicable
HTL0018318 and donepezil interaction study in elderly volunteers.Drug-Drug interaction, M1 agonist, Alzheimer, donepezil
NL-OMON28309Heptares Therapeutics Ltd.36
Completed
Phase 2
Efficacy and safety of KAL-13 in Osteoarthritis
CTRI/2017/12/010899Kerala Ayurveda Limited150
Completed
Not Applicable
Midazolam at end of the surgery - does it prevent emergence agitation?
CTRI/2018/09/015790Hinduja National Hospital64
Completed
Phase 4
Does infiltration of local anaesthesia improve recovery after anterior hip replacement?total hip replacementlocal infiltration analgesiapostoperative recoveryAnaesthesiology - Pain managementMusculoskeletal - OsteoarthritisMusculoskeletal - Other muscular and skeletal disorders
ACTRN12615000844549Dr Nicole Tan160
Completed
Not Applicable
A randomised prospective double-blind, placebo controlled trial of prophylactic oral levofloxacin following chemotherapy for lymphoma and solid tumoursBreast, testis, lung (small cell), lymphoma (Hodgkins), lymphoma (non-Hodgkins)Complications of procedures, not elsewhere classifiedCancer
ISRCTN49693355Cancer Research UK (CRUK) (UK)1,500
Safety and Immunogenicity of CJ-50300 | Clinical Trial